Hikma Pharma Gets Preliminary FTC Approval For Acquisition Of Custopharm

Hikma Pharmaceuticals PLC (HIK,HIK.L) said the Group will now work towards closing its acquisition of Custopharm Inc. from Water Street Healthcare Partners. Hikma confirmed it has received preliminary approval from the US Federal Trade Commission, or FTC.

The transaction was announced in September of last year. The companies have now obtained all regulatory approvals required to close the acquisition deal. Hikma noted that it will make a further announcement upon the close of the transaction.

Carlsbad, California -based Custopharm markets its products in the US through its commercial arm Leucadia Pharmaceuticals.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT